Tag: Kisunla

Over 6 million Americans are affected by Alzheimer's disease, a leading cause of cognitive decline. Recent advances have led to FDA approval of new medications for cognitive decline, including Leqembi (lecanemab) and Kisunla (donanemab), marking a new era in treatment by targeting the underlying pathology.

In July 2024, the U.S. Food and Drug Administration (FDA) approved donanemab, also known as Kisunla, for the treatment of early symptomatic Alzheimer's disease. If you are wondering **what is the Eli Lilly memory drug**, Kisunla represents a significant advancement by targeting the underlying pathology of the disease rather than just managing symptoms.

Following its full FDA approval in July 2024, Eli Lilly's Alzheimer's treatment, Kisunla (donanemab), was launched with a list price of $32,000 for a year of treatment. The final cost to patients for this disease-modifying therapy can vary significantly based on treatment duration, insurance coverage, and additional monitoring requirements.

In clinical trials for donanemab (brand name Kisunla), approximately 37% of participants experienced amyloid-related imaging abnormalities (ARIA), a key safety consideration for this Alzheimer's treatment. Understanding **what are the side effects of the drug donanemab?** is crucial for patients, caregivers, and clinicians considering this therapy.

As of 2025, the U.S. Food and Drug Administration (FDA) has granted full approval to two amyloid antibodies for treating early-stage Alzheimer's disease: lecanemab (Leqembi) and donanemab (Kisunla) [1.2.1, 1.2.3, 1.2.4]. This article answers: **what amyloid antibodies are FDA approved** and details their use.

In July 2024, the FDA granted traditional approval for **donanemab** (marketed as Kisunla™), a monoclonal antibody that targets and helps clear amyloid plaques in patients with early symptomatic Alzheimer's disease. This represents a significant advancement in treating the underlying pathology of the disease rather than just managing symptoms.

With a market capitalization exceeding $750 billion as of 2024, Eli Lilly is a global pharmaceutical leader. Answering the question, "What is the Eli Lilly drug?" is complex, as the company develops and markets a diverse portfolio of treatments. However, recent successes in metabolic and neurologic health have propelled drugs like Mounjaro, Zepbound, and Kisunla to the forefront of its identity.

The U.S. Food and Drug Administration (FDA) approved donanemab (brand name Kisunla) in July 2024 for treating early symptomatic Alzheimer's disease. This monoclonal antibody, developed by Eli Lilly, is specifically designed to target and help clear beta-amyloid plaques from the brain. Understanding the meaning of Donanemab involves grasping its innovative mechanism and potential to slow the disease's progression.